HRMY — Harmony Biosciences Holdings, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1802665 ·
Last close
$33.01
Market Cap
$1.94B
52W High
$43.49
52W Low
$25.90
ADV30
1,094,091
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 268,917,000 188,231,000 54,197,000 48,196,000 1,478,245,000 647,099,000 406,013,000
Jun 2026 261,280,000 198,082,000 89,316,000 75,431,000 1,373,084,000 549,769,000 373,841,000
Mar 2026 215,387,000 170,875,000 37,291,000 32,488,000 1,271,824,000 589,398,000 361,475,000
Dec 2025 243,776,000 175,231,000 38,557,000 22,486,000 1,271,631,000 752,502,000 401,413,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$323,036,000
Investing CF
$-325,105,000
Financing CF
$2,169,000
CapEx
$-310,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$3.02
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$317,018,000
Inventory
$5,871,000
Receivables
$127,739,000
ST Investments
$124,039,000
EBIT TTM
$245,871,000
Pretax Income TTM
$232,961,000
Interest Exp TTM
$12,910,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$989,360,000
EBITDA
$244,696,992
Free Cash Flow
$191,779,872
Enterprise Value
$1,328,101,120
Total Cash
$771,137,984
Total Debt
$154,914,000
Shares Out
58,723,199
Trailing EPS
$3.02
Book Value
$18.26
ROE
18.7%
ROA
10.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 868,453,000 208,469,000 158,687,000 1,271,631,000 401,413,000 870,218,000 348,199,000
Dec 2024 714,734,000 190,826,000 145,493,000 999,200,000 340,045,000 659,155,000 219,821,000
Dec 2023 582,022,000 192,030,000 128,853,000 811,448,000 344,456,000 466,992,000 219,387,000
Dec 2022 437,855,000 120,186,000 181,468,000 673,870,000 271,032,000 402,838,000 144,466,000

TTM Snapshot

Revenues TTM
$959,898,000
NetIncome TTM
$181,270,000
OpCashFlow TTM
—
Assets (Latest)
$1,373,084,000
Forward EPS
$7.00

Max Pain — expiry 2026-12-18

max pain strike: $37.50 · spot: $33.11 · call oi: 2,434 · put oi: 12,539
Expected Move to 2026-12-18: ±$4.15 (12.53%) — implied range $28.96 – $37.26 · ATM straddle on $32.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TRVI Trevi Therapeutics, Inc. $1.93B $13.51 —
SEPN Septerna, Inc. $1.90B $40.02 —
VERA Vera Therapeutics, Inc. $1.89B $26.20 —
ZBIO Zenas BioPharma, Inc. $1.88B $27.75 —
BHVN Biohaven Ltd. $2.00B $13.24 —

News headlines (Yahoo Finance, 1h cache)

Harmony Biosciences (HRMY) Stock May Be Undervalued On Earnings Power
2026-11-07 04:25 · Yahoo
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
2026-11-05 18:04 · Yahoo
Harmony Biosciences Holdings, Inc. Q3 2026 Earnings Call Summary
2026-11-04 22:30 · Yahoo
Harmony Biosciences (HRMY) Q3 2026 Earnings Call Transcript
2026-11-04 19:45 · Yahoo
Harmony Biosciences Q3 Earnings Call Highlights
2026-11-04 18:14 · Yahoo
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
2026-11-04 12:55 · Yahoo
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
2026-10-28 13:00 · Yahoo
HRMY or ARGX: Which Is the Better Value Stock Right Now?
2026-10-22 14:40 · Yahoo
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
2026-10-22 12:40 · Yahoo
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
2026-10-20 12:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.